Sign In
Buy AKBA
$0.84
-0.0659 (-7.24%)
At Close: Aug 10, 2026
CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 05'th Jan 2026
CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,
Assenagon Asset Management S.A. Makes New Investment in Akebia Therapeutics, Inc. $AKBA
03:20am, Thursday, 25'th Dec 2025
Assenagon Asset Management S.A. acquired a new stake in shares of Akebia Therapeutics, Inc. (NASDAQ: AKBA) in the third quarter, according to the company in its most recent Form 13F filing with the Se
Comparing NLS Pharmaceutics (NASDAQ:NCEL) & Akebia Therapeutics (NASDAQ:AKBA)
01:40am, Thursday, 04'th Dec 2025
NLS Pharmaceutics (NASDAQ: NCEL - Get Free Report) and Akebia Therapeutics (NASDAQ: AKBA - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast t
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 01'st Dec 2025
CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,
Q32 Bio Sells Complement Inhibitor ADX-097
07:00am, Monday, 01'st Dec 2025
-- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata -- -- $12 million in upfront and guaranteed near-term milestone payments expected to extend cash ru
Akebia Announces Establishment of Rare Kidney Disease Pipeline
07:00am, Monday, 01'st Dec 2025
Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease ind
Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
08:00am, Monday, 24'th Nov 2025
CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,
Acadian Asset Management LLC Takes Position in Akebia Therapeutics, Inc. $AKBA
03:15am, Friday, 14'th Nov 2025
Acadian Asset Management LLC acquired a new position in shares of Akebia Therapeutics, Inc. (NASDAQ: AKBA) in the undefined quarter, according to the company in its most recent disclosure with the Sec
Akebia Therapeutics (AKBA) Loses 39.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:35am, Tuesday, 11'th Nov 2025
The heavy selling pressure might have exhausted for Akebia Therapeutics (AKBA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street
Akebia Therapeutics, Inc. (AKBA) Q3 2025 Earnings Call Transcript
11:01am, Monday, 10'th Nov 2025
Akebia Therapeutics, Inc. ( AKBA ) Q3 2025 Earnings Call November 10, 2025 8:00 AM EST Company Participants Mercedes Carrasco - Senior Director of Investor & Corporate Communications John Butler - CEO
Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
07:00am, Monday, 10'th Nov 2025
Vafseo® (vadadustat) Q3 2025 net product revenues grew to $14.3 million ; Q3 2025 total net product revenues were $56.8 million Operational pilot of Vafseo at DaVita expected to complete in the fou
Win-Odds Analysis Presented at American Society of Nephrology Kidney Week 2025 Win-Odds Analysis Presented at American Society of Nephrology Kidney Week 2025
Akebia Therapeutics to Present at Upcoming Investor Conferences
08:00am, Tuesday, 04'th Nov 2025
CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 03'rd Nov 2025
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,
